113 related articles for article (PubMed ID: 30845340)
1. Cardiometabolic risk factors in young women with macroprolactinaemia.
Krysiak R; Marek B; Okopień B
Endokrynol Pol; 2019; 70(4):336-341. PubMed ID: 30845340
[TBL] [Abstract][Full Text] [Related]
2. Macroprolactinaemia modulates cardiometabolic effects of fenofibrate in men with atherogenic dyslipidaemia: A pilot study.
Krysiak R; Kowalcze K; Okopień B
J Clin Pharm Ther; 2020 Feb; 45(1):115-121. PubMed ID: 31444987
[TBL] [Abstract][Full Text] [Related]
3. Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study.
Krysiak R; Szkróbka W; Okopień B
Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):7-13. PubMed ID: 31185509
[TBL] [Abstract][Full Text] [Related]
4. Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia.
Krysiak R; Kowalcze K; Okopień B
Am J Cardiol; 2019 Oct; 124(8):1207-1212. PubMed ID: 31409451
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia.
Krysiak R; Kowalcze K; Okopień B
J Clin Pharmacol; 2023 Aug; 63(8):886-894. PubMed ID: 37042432
[TBL] [Abstract][Full Text] [Related]
6. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2019 Feb; 71(1):61-66. PubMed ID: 30469130
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D Status Determines Cardiometabolic Effects of Cabergoline in Women with Elevated Prolactin Levels: A Pilot Study.
Krysiak R; Basiak M; Machnik G; Szkróbka W; Okopień B
Nutrients; 2023 May; 15(10):. PubMed ID: 37242186
[TBL] [Abstract][Full Text] [Related]
8. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
9. Impaired Cardiometabolic Effects of Bromocriptine in Men With Early-Onset Androgenic Alopecia.
Krysiak R; Basiak M; Szkróbka W; Okopień B
J Clin Pharmacol; 2023 Mar; 63(3):345-351. PubMed ID: 36222207
[TBL] [Abstract][Full Text] [Related]
10. Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia.
Krysiak R; Szkróbka W; Okopień B
J Clin Pharmacol; 2019 Jan; 59(1):83-89. PubMed ID: 30129670
[TBL] [Abstract][Full Text] [Related]
11. Cardiometabolic profile of young women with hypoprolactinemia.
Krysiak R; Kowalcze K; Okopień B
Endocrine; 2022 Oct; 78(1):135-141. PubMed ID: 35906342
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study.
Krysiak R; Kowalcze K; Okopień B
Cardiology; 2022; 147(5-6):497-506. PubMed ID: 36195057
[TBL] [Abstract][Full Text] [Related]
13. The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
Krysiak R; Okrzesik J; Szkrobka W; Okopień B
Pharmacol Rep; 2016 Feb; 68(1):185-9. PubMed ID: 26721371
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Krysiak R; Gilowski W; Szkrobka W; Okopien B
Cardiovasc Ther; 2015 Oct; 33(5):282-7. PubMed ID: 26146893
[TBL] [Abstract][Full Text] [Related]
15. The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome.
Krysiak R; Szkróbka W; Okopień B
Pharmacol Rep; 2021 Feb; 73(1):261-268. PubMed ID: 32696349
[TBL] [Abstract][Full Text] [Related]
16. Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers.
Hattori N; Ishihara T; Saiki Y
Clin Endocrinol (Oxf); 2009 Nov; 71(5):702-8. PubMed ID: 19486017
[TBL] [Abstract][Full Text] [Related]
17. Screening for macroprolactinaemia and pituitary imaging studies.
Hauache OM; Rocha AJ; Maia AC; Maciel RM; Vieira JG
Clin Endocrinol (Oxf); 2002 Sep; 57(3):327-31. PubMed ID: 12201824
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Atorvastatin on Cardiometabolic Risk Factors in Sisters of Women with Polycystic Ovary Syndrome.
Krysiak R; Kowalcze K; Okopień B
Pharmacology; 2023; 108(5):451-459. PubMed ID: 37536301
[TBL] [Abstract][Full Text] [Related]
19. Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis.
Krysiak R; Kowalcze K; Okopień B
Pharmacology; 2023; 108(3):255-264. PubMed ID: 36878199
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Metformin and Metformin-Testosterone Combination on Cardiometabolic Risk Factors in Men with Late-onset Hypogonadism and Impaired Glucose Tolerance.
Krysiak R; Gilowski W; Okopien B
Exp Clin Endocrinol Diabetes; 2015 Nov; 123(10):608-13. PubMed ID: 26600057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
